IDEAYA Biosciences (IDYA) investor relations material

Market opportunity and growth strategy

• Spine surgery market estimated at $10 billion, with company penetration just under 10%.

• Lateral surgery market sized at $1 billion, identified as a faster-growing segment due to clinical benefits like lower blood loss and faster recovery.

• Focus on procedural adoption and clinical distinction to drive surgeon adoption and expand market share.

• Consistent 20% quarterly growth in surgeon adoption since 2024, underpinned by compelling procedural offerings.

• International strategy targets deep penetration in select countries, building direct sales and higher profitability.

Innovation and product development

• Lateral surgery platform (PTP/LTP) addresses hurdles to broader adoption, with investments in patient positioning and neural monitoring.

• EOS imaging system and EOS Insight software enable longitudinal patient data analysis and predictive modeling for surgical planning.

• Launch of Valence navigation and surgical robot platform integrated into PTP to enhance reproducibility and surgeon confidence.

• Valence allows navigation and robotic placement for multiple surgical steps, broadening accessibility for less experienced surgeons.

• Expansion into ALIF, cervical, and deformity procedures as surgeon confidence with core platforms grows.

Financial performance and outlook

• Revenue per procedure averages $12,000 over the past 12 months, reflecting strong capture of procedural value.

• Profitability improved from negative to positive adjusted EBITDA in 2024, with positive cash flow projected for 2025 and 2026.

• Refinanced $200 million in term debt, saving 300 basis points in interest and $6 million annually.

• 2026 guidance includes 15% top-line growth to $882 million, $134 million EBITDA, and $20 million free cash flow.

• Scalable infrastructure investments expected to drive continued profitability and cash flow growth.